Podcasts about Genentech

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with Erin Gillaspie, MD, MPH, and Laurie Matt-Amaral, MD, MPH, about navigating challenges as women in oncology, investing in relationships and more. ·       Gillaspie and Matt-Amaral share their journeys within their fields. 2:37 ·       Have you ever experienced imposter syndrome? 9:26 ·       How did you navigate moments when it felt like you had hit a wall? 10:36 ·       How have you balanced family life and your career? 21:25 ·       If you had to give two or three tips for up-and-coming women physicians, what would they be? 30:07 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Gillaspie can be reached at eringillaspie@creighton.edu or on Instagram @dreringillaspie. Matt-Amaral can be reached at mattaml@ccf.org. Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.

How do you help others truly understand what it's like to live with food allergies? Through the power of storytelling. In this episode, we explore Food Allergies in the City, a new micro-drama series inspired by the real experiences of young adults living with food allergies. FAACT helped bring authentic community voices to the project, and we're joined by Del Conyers, Genentech's Director of Patient Advocacy Relations, and FAACT Director of Marketing, Lisa Horne, to discuss how storytelling can educate, inspire, and raise food allergy awareness in a whole new way. Resources to keep you in the know:Food Allergies in the City: Watch the 4-part, micro-drama seriesYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: GenentechThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Lefkowitz was told in 1973 that hormone receptors were a figment of his imagination. The work that proved otherwise became the molecular foundation of GPCR pharmacology.Nobel laureate Robert Lefkowitz traces the full arc of GPCR discovery — from developing the first radioligand for the beta-adrenergic receptor to purifying it, cloning it, and watching a sequencing run reveal structural homology with rhodopsin that nobody in the field had predicted. That 1986 paper established the GPCR superfamily. The same system yielded the GRK family and the beta-arrestins. This conversation is also about the human architecture behind that science: how a Vietnam War draft assignment in 1968 redirected a physician toward a question the field wasn't sure was real, what 18 months of unbroken failure at the NIH taught him about research, and why he argues that if 50% of your experiments succeed, you are not working on hard enough problems.How a Vietnam War draft sent a physician to the NIH — and gave rise to 50 years of GPCR receptor pharmacologyWhy Lefkowitz chose the beta-adrenergic system, and why he considers it the smartest scientific decision of his careerThe cloning race against Genentech: the "stupid idea" that worked and the intronless gene that ended the competitionHigh output vs. low output failure — how to find the research territory between trivial problems and intractable onesWhat the Nobel call at 5 AM actually felt like: not jubilation, but relief — and a tear when he learned who he'd share it withDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Send us Fan MailEveryone talks about getting humans to Mars. But almost nobody talks about the harder question - how do you keep them alive once they get there? My guest today says the answer isn't bigger rockets - it's plants.Mark Ciotola is CEO and Co-Founder of Sustain Space ( https://www.sustainspace.com/ ), a company focused on developing regenerative life-support technologies for future space missions while translating those innovations to improve agriculture and sustainability on Earth. Through Sustain Space's Orbital Genomics initiative, he is helping advance research into growing plants in space environments - an essential capability for long-duration missions to the Moon, Mars, and beyond.Mark's career spans entrepreneurship, academia, industry, and government, including work with NASA, Genentech, Applied Biosystems, Intuit, Carnegie Mellon University, Monash University, San Francisco State University, and Singularity University, where he served as Entrepreneur-in-Residence and faculty member in Space and Physical Sciences.A physicist, entrepreneur, educator, and sustainability advocate, Mark is particularly interested in regenerative ecosystems, closed-loop life-support systems, space agriculture, and the broader question of how humanity can build a sustainable future both on Earth and beyond it.Important Episode Link - HudsonAlpha Institute for Biotechnology -https://www.hudsonalpha.org/#MarkCiotola #SustainSpace #SpaceAgriculture #SpaceFarming #MarsColonization #MoonBase #NASA #SpaceBiology #Astrobiology #PlantScience #OrbitalGenomics #ControlledEnvironmentAgriculture #VerticalFarming #Hydroponics #SyntheticBiology #FutureOfFood #SpaceTechnology #SpaceExploration #LifeSupportSystems #ClosedLoopSystems #MarsMission #MoonMission #Humanity #Innovation #SciencePodcast #STEM #FutureOfHumanity #ProgressPotentialPossibilitiesSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Serin Silva is an intuitive strategic advisor and executive coach who helps powerhouse women move from stuck to strategic growth. After two decades leading transformation as a VP at Fortune 500 companies, including taking Williams-Sonoma to half a billion in sales and launching Hearst Corporation's first digital division, Serin now guides CEOs and executives to make clear, confident, and energetically aligned decisions in the moments that matter most. Her work blends sharp business strategy with intuitive insight, a rare combination that's helped clients scale from $10M to $25M, land CEO roles, and transform from self-doubt to self-belief. Serin helps high-achieving women recalibrate how they lead, turning overwhelm into clarity and performance into purpose. Her clients include leaders from Apple, Patreon, Airbnb, Genentech, UCLA, and Microsoft.  

Most clinical research treats patients like data points. What gets lost when researchers stop listening to the people they study, and what does it cost the science itself? Niharika Singh is a biomedical engineer and pre-medical student with research experience at Genentech, Abbott, AstraZeneca, and the Keck School of Medicine, and a global ambassador with the United Nations SURGhub. She discusses the KevinMD article "Patient involvement transforms modern clinical research." You will hear the difference between treating a patient as a data set, engaging them as a collaborator, and inviting their emotional and lived experience into the study design. She walks through the Tiger Project hernia training across India and Ghana, what medical device design verification taught her about surgical research, and why AI in medicine is making patient voice harder to hear. You will hear a research methodology that treats the patient's voice as data worth collecting, and a case for defending human connection as AI changes how medicine is practiced. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Send us Fan MailFor decades, oncologists have had to wait until cancer became visible on a scan before knowing whether it had returned. But what if doctors could detect microscopic traces of cancer months earlier with a simple blood draw - and use that information to decide who actually needs treatment? Today we're exploring a breakthrough that may fundamentally change the way cancer is monitored and treated.Eric Matthews is General Manager of Biopharma at Natera ( https://www.natera.com/ ), a leader in personalized molecular diagnostics and the company behind Signatera, the first FDA-approved molecular residual disease companion diagnostic.Over the past 25 years, Eric has helped bring nine medicines to market across nineteen indication launches, building a career at the forefront of oncology, precision medicine, and biopharmaceutical innovation.Before joining Natera, Eric served as Chief Business Officer at Caris Life Sciences, where he focused on diagnostic, data, and drug discovery partnerships. Prior to that, he was Chief Commercial Officer at Arcus Biosciences, helping forge major strategic collaborations including Arcus' landmark partnership with Gilead Sciences.Eric's previous leadership roles include Vice President of Global Marketing for Immuno-Oncology at AstraZeneca and commercial leadership positions at Genentech and Roche, where he worked on some of the most influential cancer therapies of the modern era, including Avastin and Tecentriq.Eric holds an MBA in Health Sector Management, a Master's in Health Policy and Economics, and dual bachelor's degrees in Molecular Biology and Economics from Duke University.Today we discuss the future of molecular residual disease testing, how personalized blood-based diagnostics are changing cancer care, the recent FDA approval of Signatera as the first MRD companion diagnostic, and what the next decade may hold for truly individualized oncology.#CancerResearch #CancerDetection #PrecisionMedicine #Oncology #LiquidBiopsy #Signatera #Natera #CancerCare #Biotech #HealthcareInnovation #Immunotherapy #Tecentriq #BladderCancer #MolecularBiology #PersonalizedMedicine #CancerTreatment #MedicalInnovation #FutureOfMedicine #Biotechnology #ProgressPotentialPossibilitiesSupport the show

Moderna's mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review.Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics, which hit the market with $625 million in April, outpacing Moderna's 2018 IPO of $600 million. And now we have Parabilis Medicines, which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million.Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech.Genentech also made a big change last week.Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer's disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma's $2.3 billion acquisition of Ajax Therapeutics in April.Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner's National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi's diabetes drug Tzield was greenlit for older kids and teenagers, though it's unclear whether a voucher was associated with the approval. Meanwhile, Disc Medicine's rejected rare disease drug bitopertin appears to be back on track, with the biotech announcing last week that the FDA will allow its current Phase 3 trial to support another regulatory filing.

Send us Fan MailWe're living through the fastest technological acceleration in human history.Every week brings a new AI model, a new productivity tool, and a new prediction that everything is about to change forever.And yet somehow, most people feel less focused, less certain, and more overwhelmed than ever.In this episode of FUTUREPROOF., I sit down with Fredric Marshall, author of THRIVE: The Antidote to Future Shock, to explore a possibility we don't talk about enough:What if the biggest risk of AI isn't that it replaces humans?What if it's that it exhausts them?Fred has spent decades helping organizations like Apple, Pfizer, and Genentech navigate periods of intense change. His argument is that most organizations aren't suffering from a technology problem. They're suffering from an attention problem.We're surrounded by tools designed to save time, yet nobody seems to have any.We have more information than ever, yet many leaders feel less certain.And we keep calling it a productivity problem when it may actually be a human capacity problem.We discuss: Why "future shock" may be the defining leadership challenge of the AI era  How AI can reduce friction—or quietly create more of it  Why burnout is often a systems problem disguised as a personal one  The hidden cost of constant context switching  Why clarity may become more valuable than speed  How leaders can separate signal from noise  What it actually means to thrive during exponential change Because if every problem gets solved with another app, another dashboard, or another AI assistant...At some point, someone has to manage all those solutions.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Let Babies Eat: New Guidelines to Prevent Food Allergies FACULTY: David Stukus, MD is a Professor of Clinical Pediatrics and the Director of the Food Allergy Treatment Center at Nationwide Children's Hospital and the Ohio State University College of Medicine.   OVERVIEW: In this grand rounds episode of Pediatrics Now, host Holly Wayment brings us cutting-edge approaches to infant food introduction and allergy prevention, featuring Nationwide Children's Hospital's Dr. David Stukus .   Dr. Stukus delves into the history of infant feeding guidelines, the evolving scientific evidence, and practical strategies for pediatric practitioners. Listeners will gain insights into the confusion caused by changing guidelines, the landmark LEAP trial's impact on peanut allergy prevention, and the importance of introducing allergenic foods early, based on evidence rather than outdated practices. The episode provides evidence-based recommendations to support parents, addressing common misconceptions and fears about food allergies.   Join the discussion to better understand the relationship between eczema and food allergies, how to effectively reassure and guide families during clinics, and strategies to help pediatric patients achieve diverse diets that minimize allergy risks. Learn how pediatricians play a crucial role in educating families and preventing unnecessary dietary restrictions that can lead to food allergies. This episode is a must-listen for any healthcare professional looking to navigate the complexities of infant nutrition and allergy prevention with clarity and confidence.   OVERALL LEARNING OBJECTIVE: Increased awareness and education for pediatric providers DISCLOSURE TO LEARNERS: David Stukus, MD has disclosed he is a researcher for DBV Technologies and was a consultant to ARS Pharmaceutical and Genentech. The relevant financial relationships noted for Dr. Stukus have been mitigated.   The Pediatric Grand Rounds Planning Committee (Deepak Kamat, MD, PhD, Steven Seidner, MD, Daniel Ranch, MD and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose. The UT Health Science Center San Antonio and Deepak Kamat, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests. CONTINUING MEDICAL EDUCATION STATEMENTS: The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The UT Health Science Center San Antonio designates this live activity up to a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 0.75 MOC point in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit. CERTIFICATE OF ATTENDANCE: Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance. Credit may be obtained upon successful completion of the activity's evaluation. RELEASE DATE: 2/5/2025 EXPIRATION DATE: 8/31/2027        

In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares his real-world perspective on anti-amyloid therapy, describing a patient population that is typically early-stage, high-functioning, and has a mean age of about 60 to 70 years, and emphasizing the pharmacist's role in expectation-setting around the modest but potentially cumulative slowing of cognitive decline. The episode closes with a thorough discussion of the April 2026 Cochrane review on amyloid-targeting monoclonal antibodies, which both Marini and Sobhanian find overly broad in its conclusions. They note limitations such as the inclusion of withdrawn agents like aducanumab (Aduhelm; Biogen), heterogeneous inclusion criteria across trials, and an 18-month study horizon that may be too short to capture the full benefit suggested by longer-term open-label extension data.Key Takeaways:1. New options for Alzheimer's agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.2. Anti-amyloid therapies are imperfect but not ready to be written off. The April 2026 Cochrane review drew significant attention with its conclusion that anti-amyloid monoclonal antibodies produce only trivial cognitive benefits, but its findings are limited by the inclusion of older, withdrawn agents, heterogeneous trial populations, and an 18-month time horizon that may be too short to capture the full trajectory of benefit.3. The pharmacist's role in anti-amyloid therapy goes well beyond dispensing. As illustrated by Sobhanian's practice at the University of Maryland, clinical pharmacists embedded in neurology clinics play a critical role in patient selection, expectation-setting, ARIA counseling, and informed decision-making for patients considering anti-amyloid therapy—a complex, high-stakes treatment decision that these patients and their caregivers should never be navigating alone.

Kevin Mack, the new president of Via Licensing Alliance, joins Eli for the Clause 8 season finale.Kevin talks about Via's plans to build its next patent pools around "de facto" standards — technology the market adopted on its own, with no standards body behind it — which would push collaborative licensing into territory it has never touched. Mack also takes a hard look at the royalty-free models spreading through tech and AI, from AV1 to the new Shared AI License Foundation (SAIL), argues that "free" rarely stays free, and explains why he's optimistic about where the patent system is heading.Kevin and Eli also discuss:*Via's model and the "tipping point" that turns a pool from a few licensors into thousands of licensees*"De facto" standards: pooling patents for technology no standards body ever blessed*Leadership turnover at Via, the HEVC pool's move to Access Advance, and a new strategy-and-growth group*The push into semiconductors, including a new DRAM memory program*AV1, SAIL, and why Mack thinks royalty-free rarely stays free*Whether AI patents are as "foundational" as advertised — and why "AI is not new"*Efficient infringement, patents as property rights, and why companies ultimately take a license*The mood out of Via's Rome summit and a US patent system tilting back toward ownersNotable names, companies & standardsPeople: Kevin Mack (president, Via Licensing Alliance); Heath Hoglund (former Via president); John Amster (Jamster Capital; RPX co-founder)Organizations: Via Licensing Alliance (Via LA), MPEG LA, Dolby, Access Advance, Alliance for Open Media, Shared AI License Foundation (SAIL), WIPO (PatentScope), DOJ, USPTOSAIL founders / board (public): Anthropic, Genentech, IBM, Meta, Microsoft; board observers eBay and TD Bank Group; members include Block and FigmaStandards & technologies: AAC, AVC (H.264), HEVC (H.265), AV1, MPEG-2, Qi wireless charging, DRAM memory, SEP / FRANDDisclaimer This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.voiceofip.com

Purti Kanodia Talks Real-World AI Applications. On this episode of OWA Talks, Purti shares a practical, no-hype approach to building AI fluency. Join us as we get beyond the ‘theory' and talk implementation. If you're curious about AI but overwhelmed, this one's for you.About the guest:Purti Kanodia is a fractional AI transformation leader and founder of Clarity Prompts, an AI consulting firm and weekly newsletter that helps executives and senior leaders build AI fluency and lead practical, responsible AI adoption across their organizations.With nearly two decades of experience across optical retail, employer healthcare, management consulting, and biopharma, Purti has worked with companies including National Vision, Crossover Health, Slalom Consulting, and Genentech, always at the intersection of technology, business strategy, and human change. At National Vision, she led the launch of Toku BioAge, the first AI-based retinal imaging wellness product in US optical retail. Earlier at Slalom Consulting, she spent two years in Ophthalmology designing product strategy for AI/ML clinical decision support tools.What sets Purti apart is her whole-picture lens on technology adoption. She starts with the problem, not the technology, and believes that testing without measurement rarely survives the pilot. Getting to real scale means thinking through people, process, and organizational readiness together, not as an afterthought.She has mentored startups through Singularity University Labs, the UCSF Entrepreneurship Center, and HealthTech Capital. Purti holds a Master of Science in Biotechnology from Georgetown University and is based in the San Francisco Bay Area.Like this episode? Please subscribe and share!iTunes | Spotify | Overcast | iHeartRadio | AmazonConnect with the OWA:Website | LinkedIn | Instagram | Facebook

Kortney and Dr. Payel Gupta are joined by Tamara Hubbard, MA, LCPC, a licensed clinical professional counselor and food-allergy parent. Together, they dig into what food allergy anxiety actually looks like in teenagers, why some teens take more risks as they get older, and what parents can do to support their teens without making things worse. What we cover in this episode is about food allergy anxiety in teens: What makes teenagers a high-risk group for food allergy reactions. Independence is increasing at the exact same time parental oversight is decreasing, and that combination creates real safety concerns. What food allergy risk-taking actually looks like. It is not always what parents expect, and some of it is just teens figuring out how to belong. Food allergy social anxiety is its own distinct experience. The fear of looking different, being a burden, or standing out can drive behavior just as much as the fear of a reaction. Why parental anxiety matters more than most parents realize. The way parents talk about food allergies often directly affects how teens handle them. How to build confidence and ownership in your teen. What to do when a teen is either too anxious or not anxious enough. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

How CD38, PARP, and Leaky Gut Are Destroying Your NAD Levels | Dr. Andrew Salzman Your NAD is being drained by two hidden enzymes, your gut may be the starting point of every aging process in your body, and creatine does something to your mitochondria that has nothing to do with muscle. This episode rewrites what you thought you knew about longevity, anti-aging biology, and how your body actually produces and delivers energy at the cellular level. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR -Explore all of Wonderfeel's products at: getwonderfeel.com/dave They are gifting a complimentary 7-day Youngr™ supply (mini pouch) with every order across any of their products. The code will be DAVE, and the campaign will be active through June 6th. Host Dave Asprey sits down with Dr. Andrew Salzman, a physician, inventor, and biomedical entrepreneur with more than 30 years of experience in drug discovery and development. An alumnus of Harvard Medical School, Yale University, and Columbia University, Dr. Salzman has authored more than 170 scientific publications and holds 50 patents. He invented the original clinical-stage PARP-1 inhibitor, leading to the world's first clinical treatment for raising NAD levels and fighting cancers caused by the BRCA1 and BRCA2 genes. Genentech licensed his breakthrough technology for $600 million. His research into gastrointestinal microbiota, autoimmune disease, oxidative stress, and mitochondrial ATP production now forms the foundation of how millions of patients get treated worldwide. Dr. Salzman names the two biggest NAD drains in your body, CD38 and PARP, and explains why taking NMN or NR alone is like filling a bathtub with the drain wide open. He breaks down the formulation science behind pairing NAD precursors with CD38 blockers like hydroxytyrosol alongside PARP-reducing antioxidants like ergothioneine, and delivers a paradigm-shifting explanation of creatine as an energy distribution network inside your cells. Rather than a simple muscle supplement, creatine acts as a high-speed ATP shuttle that carries energy from your mitochondria to the precise location and moment your brain, gut, and heart need it most. You'll Learn: Why NAD declines with age and which two enzymes are primarily responsible for draining it How CD38 rises with inflammation rather than NAD levels, and what that means for your supplement strategy Why creatine is one of the most underrated anti-aging and brain optimization supplements available How creatine functions as a spatial and temporal energy delivery network for your brain, gut, and heart Why the gut may be the origin point of the entire aging process and how that cascade unfolds decade by decade How leaky gut drives systemic inflammation, crashes NAD, and accelerates biological aging throughout the body What controls tight junction integrity and how ATP, butyrate, creatine, and fasting all play a role Why most creatine supplements fail to absorb properly and what to look for in a high-quality source How to rebuild your microbiome in three to four weeks through diet alone, without antibiotics Why walking immediately after a meal may be doing more harm than good to your gut lining Thank you to our sponsors! - Screenfit | Get your at-home eye training program for 40% off using code DAVE at https://www.screenfit.com/dave. - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Pique | Go to Piquelife.com/dave for 20% off. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Dr. Andrew Salzman, NAD depletion, CD38 inhibition, PARP inhibition, NMN supplements, creatine ATP shuttle, leaky gut aging, tight junction integrity, inflammaging, lipopolysaccharide gut, flagellin toxin, butyrate gut healing, ergothioneine, hydroxytyrosol, peroxynitrite, superoxide mitochondria, creatine energy distribution, gut origin of aging, NAD bathtub analogy, BRCA PARP inhibitor, Wonderfeel, creatine monohydrate, intestinal permeability, microbiome butyrate, selective digestive decontamination, TMAO nitric oxide Resources: • Explore all of Wonderfeel's products at: getwonderfeel.com/dave • Order Youngr™: getwonderfeel.com/dave• Order ChocoCreatin™: getwonderfeel.com/dave• Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 01:12 – Introduction & BRCA Background 02:19 – DNA Damage & PARP 04:38 – Free Radicals & Oxidative Stress 11:37 – NAD & Antioxidant Defense 12:34 – CD38 & NAD Depletion 23:31 – The Gut-Aging Hypothesis 30:05 – ATP, Creatine & Energy Distribution 36:41 – Creatine as Energy Shuttle 51:09 – Microbiome & Gut Repair 59:21 – TMAO & Nitric Oxide Interference 1:03:52 – Flagellin & Gut Inflammation Research 1:09:45 – FDA & Pharmaceutical Incentives 1:16:05 – Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Quita Highsmith is the VP of population health at Genentech, but more importantly, she's a friend of The MM+M Podcast. In her third appearance on the show, she discusses Genentech's All Eyes on DME campaign featuring comedian Damon Wayans. Launched this spring, All Eyes on DME is the drugmaker's pop culture-focused way to talk about a condition in diabetic macular edema that is both often overlooked and disproportionately impacts patients of color.  Additionally, Highsmith reflects on her decades working in healthcare and why the work doesn't stop for her or Genentech.  And for our Trends segment, we're talking with our editor-at-large Steve Madden about his time in Las Vegas covering the Enhanced Games and what it means for medical marketers. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fredric Marshall spent decades helping companies including Apple, Pfizer, and Genentech solve problems in sales effectiveness, product launches, and organizational change. In this discussion, he explains why he views sales and leadership primarily as change management challenges: helping people move from where they are to where they want to be. The conversation centers on several practical ideas that shape long-term performance. Marshall argues that strong systems reduce stress because "the system is carrying the load, not you as a person or the team." He explains why high-performing people consistently invest in infrastructure, technology, and environments that remove friction and preserve attention for higher-value work. The episode also explores Marshall's "Super Eight" framework, which includes the neural net, biological health, relationships, systems, assets, and contribution. One of the central themes is that attention shapes outcomes. "Whatever you feed [neural nets], they get better at," he explains, arguing for greater discipline around information intake, habits, and social environments. Other insights from the discussion include: • Why emotionally intelligent and externally focused people often elevate entire organizations • How successful professionals balance initiative with responsiveness rather than operating in constant reaction mode • Why many entrepreneurs underestimate the value of their own time and capabilities • How journaling, repetition, and evidence gathering can gradually replace limiting beliefs • Why wealth creation often depends on investing simultaneously in productive assets and personal capability Marshall also shares research from his work studying top performers, identifying three recurring characteristics: action orientation, external focus, and the ability to question assumptions others accept too easily. The discussion is ultimately about building a life and career intentionally: curating what enters your attention, surrounding yourself with the right people, and constructing systems that support the future you are trying to create. Get Fredric's book, Thrive: The Antidote to Future Shock, here: https://tinyurl.com/smn4u5ts Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift

Sponsored by Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. Intended for US Audiences. This information is for general purposes only and is not a substitute for consulting your healthcare provider about food allergy treatment. Dr. Ari Zelig has been financially compensated by Genentech and Novartis for his participation in this episode. Today, I'm joined by Dr. Ari Zelig, a board-certified allergist and immunologist to unpack what's really happening when it comes to food allergies - and why so many more people are dealing with them today. If you are navigating food allergies, or if you've ever wondered if what you're experiencing might be more than just a sensitivity, this episode features an informative discussion on these topics! In this episode, we dive into the reality of living with food allergies, from the day-to-day challenges that families carry to the misconceptions that still exist around what an allergic reaction to food actually looks like. Dr. Zelig breaks down IgE-mediated food allergies, what's happening in the body during a reaction, and why early exposure guidelines for kids have changed. Plus, we discuss a treatment option, XOLAIR (omalizumab), an FDA-approved prescription medication for subcutaneous use that can help reduce allergic reactions to multiple foods that may occur after accidental exposure in people with IgE-mediated food allergies one year of age and up. While taking XOLAIR you should continue to avoid all foods to which you are allergic. If you or a loved one has been diagnosed with food allergies, talk to your allergist and ask about XOLAIR. You can also find more information at XOLAIR.com. XOLAIR is one of several available treatment options for IgE-mediated food allergy and it may not be appropriate for all patients. What is XOLAIR?XOLAIR®(omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR?Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:· wheezing, shortness of breath, cough, chest tightness, or trouble breathing· low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”· flushing, itching, hives, or feeling warm· swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please listen to the Important Safety Information throughout and stay tuned for additional safety information at the end of this podcast. See full Prescribing Information, including Medication Guide, at bit.ly/XOLPI. This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode. Produced by Dear Media M-US-00032583(v1.0) 5/26See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Some of the most powerful shifts in leadership come from seeing something that's been there all along, but never fully acted on.   On this episode of The Unlock Moment, I am joined by Christine Barnes, executive coach, UC Berkeley lecturer, and author of Inclusionable: Transform How You Lead and Elevate Your Team's Performance ... and her story is a brilliant example of exactly that.   Christine has spent her career inside some of the world's most complex organisations, from IBM to Oracle, Roche to Genentech, helping leaders navigate change and build capability. But it was her doctoral research - begun at an age when most of her peers were thinking about retirement - that crystallised what she had been observing for decades: that despite billions spent on diversity hiring, too many people still look up in their organisations and see nobody like them.   In this conversation, we explore why most leaders can't actually distinguish between diversity and inclusion, how Christine's own biases showed up in the middle of a research interview, and why outsourcing inclusion to DEI experts, however essential they are, lets leaders off the hook.   This is a conversation about self-awareness, accountability, and the simple but transformative idea that inclusion isn't a nice-to-have. It's your most underused leadership strategy. The Unlock Moment is hosted by Dr Gary Crotaz, PhD — master interviewer, executive coach and author. Downloaded in over 140 countries. Sign up to The Unlock Moment newsletter at https://tinyurl.com/ywhdaazp Find out more at https://garycrotaz.com and https://theunlockmoment.com Also discover his other podcasts, The Box of Keys and Unlock Your Leadership. Follow, subscribe and leave a review wherever you get your podcasts — and connect with Dr Gary on LinkedIn for more leadership insights. Part of The Unlock Moment podcast family.

Food allergy anxiety in kids is real, and it does not always look like fear. It can show up as tantrums, clinginess, control-seeking behaviors, or a child who refuses to eat at a restaurant. Child life specialist and therapist Kelsey Mora joins Kortney and Dr. Payel Gupta to unpack what is really going on.  What we cover in our episode about managing anxiety in kids Food allergy anxiety does not always look like anxiety. Tantrums, clinginess, and control-seeking behaviors can all be signs that a child is struggling. Language matters from the start. How parents explain food allergies to young children can build confidence or quietly reinforce fear. Separation anxiety and food allergies are connected. Dependence on parents can make it harder for kids to navigate school, parties, and social situations on their own. Practicing independence at home builds real-world skills. Exposure to allergens in a safe home environment teaches confidence and communication skills kids need everywhere else. Passing parental anxiety onto kids. Co-regulation starts with the caregiver, when parents are anxious, kids have a harder time calming down. Helpful resources Food allergy anxiety information from Allergy & Asthma Network Kelsey's practice and services: childlifetherapist.com  Kelsey's workbooks and resources: themethodworkbooks.com  *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn't mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United's Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Chronic lymphocytic leukemia (CLL) Clinical Trial Support Center Minimal/measurable residual disease (MRD) Patti Robinson Kaufmann First Connection ® program Online Chat Patient Community Support groups Caregiver support Lessons in Blood Cancer Video: CLL Shared Decision Making in Chronic Leukemias interactive program CLL Society Patient Power Additional Blood Cancer United Support Resources: Information Specialists Financial support Free Nutrition Consultations Free telephone/web patient programs Free booklets Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

Mia Silverman, food allergy advocate, joins us to talk about the real emotional and practical side of dating with food allergies. From what the research says about kissing risks to setting boundaries to why your allergies might actually be the best filter you have. What we cover in this episode about dating with food allergies When to tell someone about your food allergies. Mia shares why she brings up her allergies early and how she works it into her dating app profile without making it a big deal. Fear of rejection. Mia opens up about being ghosted and bullied, and how she learned to reframe rejection as a filter rather than a failure. The risks of kissing with food allergies. Dr. Gupta breaks down what the research actually says about allergens in saliva and what your partner can do to reduce the risk. Intimacy beyond kissing. From latex-free condoms to body fluids, Dr. Gupta covers what food allergy patients need to know about being safely intimate with a partner. Date ideas and setting boundaries. Mia shares practical tips for early dates, setting food-allergy rules, and keeping the conversation open without making it feel overwhelming. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

In this podcast, Greg Voisen sits down with Dr. Sheila Gujrathi, a powerhouse physician and biotech entrepreneur who reached the top of the corporate ladder only to find an "inner glass ceiling" made of fear. Despite an elite career at McKinsey and Genentech, Sheila realized her greatest battles were internal. In this episode, she breaks down the roadmap from her book, The Mirror Effect: A Transformative Approach to Growth for the Next Generation of Female Leaders, revealing how high-achievers can dismantle the hidden fears that sabotage their success. If you've ever felt like an impostor while winning, this conversation will show you how to finally flip the script.

In this episode, Michele Lamoureux sits down with Fredric Marshall, a leading expert in change management, human behavior, and helping people navigate uncertainty with confidence. Over the course of his career, Fred has worked with organizations like Apple, Pfizer, and Genentech, helping teams adapt, grow, and lead through change. But this conversation goes beyond corporate performance. Fred shares why the tools for resilience, adaptability, and growth are not reserved for high achievers or executives—they're essential skills for anyone facing change, uncertainty, overwhelm, or anxiety about the future. Drawing from decades of research and experience training more than 130,000 people across fourteen countries, Fred explains how people can move from fear and overwhelm to clarity, agency, and momentum in a rapidly changing world. We also dive into his book, THRIVE: The Antidote to Future Shock, and explore practical ways people can stay grounded and hopeful during times of disruption.   RESOURCES MENTIONED Join The Newsletter Subscribe on YouTube Follow on APPLE PODCASTS Follow on SPOTIFY PODCASTS Book: Thrive: The Antidote to Future Shock Website: https://thrivefutureyou.com/     *The Good Life with Michele Lamoureux podcast and content provided by Michele Lamoureux is for educational and entertainment purposes only. It does NOT constitute medical, mental health, professional, personal, or any kind of advice or serve as a substitute for such advice. The use of information on this podcast or materials linked from this podcast or website is at the user's own risk. Always consult a qualified healthcare or trusted provider for any decisions regarding your health and wellbeing. This episode may contain affiliate links.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

In this podcast, Greg Voisen sits down with Dr. Sheila Gujrathi, a powerhouse physician and biotech entrepreneur who reached the top of the corporate ladder only to find an "inner glass ceiling" made of fear. Despite an elite career at McKinsey and Genentech, Sheila realized her greatest battles were internal. In this episode, she breaks down the roadmap from her book, The Mirror Effect: A Transformative Approach to Growth for the Next Generation of Female Leaders, revealing how high-achievers can dismantle the hidden fears that sabotage their success. If you've ever felt like an impostor while winning, this conversation will show you how to finally flip the script.

On this week's Tech Nation, we celebrate the 50th anniversary of the first biotech company to go public, Genentech. Moira speaks with CEO Ashley Magargee about the company's journey since its founding 50 years ago, and where they're going next. Then, we remember the life of the late Dr. Craig Venter, whose efforts catalysed the race to decode the first human genome.

Fred Marshall is a pioneer in identifying the behavioral patterns of top performers and scaling them across global organizations. Having worked with companies like Apple, Pfizer, and Genentech, Fred has trained over 130,000 professionals in 14+ countries and helped launch dozens of biopharma brands generating billions in revenue. In this episode, he shares how entrepreneurs can think strategically about growth, innovation, and building businesses that actually work. On this episode we talk about: Fred's early entrepreneurial experiments and what they taught him about scaling Why combining fun and work leads to better long-term success The “Uncle Bill strategy” for gaining experience before starting a business How unit economics determine whether a business succeeds or fails Leveraging AI, delegation, and systems to scale beyond yourself Top 3 Takeaways If your unit economics don't work, your business doesn't work—no matter how great the product is. Work for others strategically to learn the model, then improve and build your own version. The key to scaling is shifting from “How can I do this?” to “How can this get done?” Notable Quotes “Instead of asking how can I do this, ask how can this get done.” “If you're not enjoying your work, you should rethink what you're doing—this is most of your life.” “Every bit of knowledge is useful—you just never know when it will pay off.” Connect with Fred Marshall: LinkedIn: https://www.linkedin.com/in/fredric-marshall-1984bb/ Instagram: https://www.instagram.com/officialfredricmarshall/ Other: https://thrivefutureyou.com  Travis Makes Money is made possible by High Level – the All-In-One Sales & Marketing Platform built for agencies, by an agency.  Capture leads, nurture them, and close more deals—all from one powerful platform.  Get an extended free trial at gohighlevel.com/travis Learn more about your ad choices. Visit megaphone.fm/adchoices

When a child is diagnosed with a food allergy, one of the first things many parents wonder is, "Did I do something wrong?" and "Did I cause my child's food allergy?" You question if it was something you ate or didn't eat during pregnancy, whether you breastfed long enough, or if you introduced foods too late. The guilt is real, and it is incredibly common. Kortney and Dr. Payel Gupta sit down with Dr. Joanne Moreau, a board-certified allergist and immunologist, to unpack exactly how food allergies develop, and why no parent should carry the weight of blame. What we cover in this episode about food allergy development and parent guilt How food allergies develop. The immune system, genetics, and environment all play a role, and science is still uncovering why. Food allergy genetics and family history. A parent with asthma, eczema, or hay fever raises a child's risk, even without a food allergy themselves. Pregnancy diet, breastfeeding, and food allergy. No conclusive evidence links what a mother eats during pregnancy, or whether she breastfeeds, to whether a child develops food allergies. Eczema and food allergy. Cracked or inflamed skin lets food proteins in before the gut can build tolerance, which can trigger sensitization. Early allergen introduction. Introducing allergenic foods between 4 and 6 months of age, and keeping them in the diet consistently, is one of the best tools we have. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.  

Shashi Shankar, CEO of Novellia,  focuses on enabling patients with serious medical conditions to consolidate their medical history into a single record using a free app.  The business model provides anonymized real-world data to pharmaceutical companies for research, clinical trial recruitment, and the acceleration of new therapy development. Artificial intelligence is used to help patients make sense of their fragmented medical records, identify clinical trials, and better understand drug safety profiles and therapeutic effectiveness.  Shashi explains, "In a nutshell, what we do is we help folks living with serious and complex medical conditions find access to and then collect all of their medical records going back 20 plus years across different physicians, sites of care, labs, and insurance into one always continuously updated record that then helps them manage and navigate their course of care." "I actually spent months of my career working at Genentech and Roche, working on a number of different cancer therapeutics, and it was an amazing opportunity, and you get to meet so many different patient communities. But one of the most difficult parts, I think, for anybody who's working on developing new medications and new therapies, is that you need to really understand the communities that you hope to serve one day. And unfortunately, a lot of data that exists right now doesn't actually capture the true patient journey. And it's not very representative of the communities that are dealing with and trying to navigate all of these different conditions." "The benefit of being able to share this data with researchers in a way that's anonymous and de- identified, so patient data is always totally secure and always held private by Novellia. The benefit of this is that researchers are able to finally understand the full journey of patients and think through how their therapies can actually help those who are trying to navigate their care."  #Novellia#HealthcareInnovation #PatientEmpowerment #DigitalHealth #HealthTech #MedicalRecords #AIinHealthcare #PatientCenteredCare #HealthcareData #ClinicalTrials #Oncology #PharmaceuticalResearch #HealthIT Novellia.com Download the transcript here

Shashi Shankar, CEO of Novellia,  focuses on enabling patients with serious medical conditions to consolidate their medical history into a single record using a free app.  The business model provides anonymized real-world data to pharmaceutical companies for research, clinical trial recruitment, and the acceleration of new therapy development. Artificial intelligence is used to help patients make sense of their fragmented medical records, identify clinical trials, and better understand drug safety profiles and therapeutic effectiveness.  Shashi explains, "In a nutshell, what we do is we help folks living with serious and complex medical conditions find access to and then collect all of their medical records going back 20 plus years across different physicians, sites of care, labs, and insurance into one always continuously updated record that then helps them manage and navigate their course of care." "I actually spent months of my career working at Genentech and Roche, working on a number of different cancer therapeutics, and it was an amazing opportunity, and you get to meet so many different patient communities. But one of the most difficult parts, I think, for anybody who's working on developing new medications and new therapies, is that you need to really understand the communities that you hope to serve one day. And unfortunately, a lot of data that exists right now doesn't actually capture the true patient journey. And it's not very representative of the communities that are dealing with and trying to navigate all of these different conditions." "The benefit of being able to share this data with researchers in a way that's anonymous and de- identified, so patient data is always totally secure and always held private by Novellia. The benefit of this is that researchers are able to finally understand the full journey of patients and think through how their therapies can actually help those who are trying to navigate their care."  #Novellia#HealthcareInnovation #PatientEmpowerment #DigitalHealth #HealthTech #MedicalRecords #AIinHealthcare #PatientCenteredCare #HealthcareData #ClinicalTrials #Oncology #PharmaceuticalResearch #HealthIT Novellia.com Listen to the podcast here

Rebecca Olin, MD, MSCE Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today. Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Acute myeloid leukemia Allogeneic stem cell transplantation Clinical Trial Support Center Beat AML® Master Clinical Trial Beat AML® press release – January 2026 Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Support groups Caregiver support Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Astellas Pharma US Inc.; Daiichi Sankyo Inc.; Debiopharm; Genentech, A Member of the Roche Group; and Kura Oncology, Inc. The post Acute Myeloid Leukemia (AML): New Approaches For A Complex Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.

Food allergy bullying is more common than most parents realize, and most kids never bring it up on their own. Research shows it affects up to 1 in 3 children with food allergies, and the signs can be easy to miss: a lunchbox that keeps coming home full, a sudden reluctance to go to school, or quietly backing off from safe food habits to avoid standing out. In this episode, psychologist Dr. Amanda Whitehouse joins Kortney and Dr. Payel Gupta to talk about what food allergy bullying actually looks like, how to start a conversation with your child without shutting them down, and when and how to bring the school into it. What we cover in this episode about food allergy bullying What food allergy bullying looks like. From verbal teasing and social exclusion to threats involving allergens, and how it differs from everyday teasing. Signs your child may be being bullied. Behavioral shifts to watch for include school avoidance, changes in eating habits, and withdrawal from activities they used to love. How to start the conversation. Why open-ended questions and connection before action are key to getting your child to open up. When and how to involve the school. How to approach teachers and administrators, know your child's rights, and document what's happening. Building resilience after bullying. How involving your child in the solution, rather than swooping in to fix it, helps them feel empowered rather than powerless. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Your favorite science podcast is back! To kick off season seven of Two Scientists Walk Into a Bar, hosts Maria Wilson and Danielle Mandikian sit down to celebrate a decade of the podcast and look back at our previous season on unmet medical needs. But what's next? Get ready for a season that's going bigger than ever before. To mark the 50th anniversary of Genentech, Maria and Danielle will draw a thread from the seminal breakthroughs of the last 50 years in biotechnology to the incredible innovations that will shape the next decade and beyond. Read the full text transcript at www.gene.com/stories/season-seven-teaser